Engflag

Dermox

Quick links to important sections

Dermox

Dermox_EN

Method of action: Antipsoriatic, Hypopigmentation Agent, Photosensitizing

Treatment option: Vitiligo, Psoriasis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermox

Property Description
Active Ingredient Methoxsalen (8-MOP)
Form Capsules, Topical Lotion, Sterile Solution
Pharmacological Class Photosensitizing Agent (Psoralen)
General Purpose Light-activated control of cell proliferation
Origin Naturally derived furocoumarin

Dermox is a brand name for a potent, prescription-only medicine containing the active substance Methoxsalen, which is used exclusively as a component of specialized light therapy procedures, known generally as photochemotherapy. It belongs to the high-level pharmacological class of Photosensitizing Agents and is chemically defined as a Psoralen compound. The regulatory status and unique mechanism of this compound have been clinically recognized by major health authorities, confirming its established role in light-based treatments.

Methoxsalen, also known scientifically as 8-Methoxypsoralen or 8-MOP, is a unique, naturally derived substance; it is a furocoumarin originally isolated from plants like Ammi majus and Psoralea corylifolia. Its designation as a photosensitizer means the drug is chemically inert until it is exposed to specific UVA radiation. This photoactivation principle is fundamental, defining its specialized use in controlled clinical environments. The required pairing with light makes it distinct from standard systemic or topical monotherapies.

The medicine is supplied in various dosage form(s) required for both systemic and topical administration. Methoxsalen is available as oral capsules for internal absorption, a topical lotion for dermal application, and a sterile solution suitable for specialized parenteral use in extracorporeal photopheresis. The general therapeutic role of the drug is to influence cellular growth and pigmentation by specifically slowing down the rapid, excessive division of certain cells when they are targeted by controlled UVA light, a process commonly used to manage conditions like severe, refractory psoriasis.

Regulatory References

  1. NIH DailyMed Methoxsalen Label

What side effects are possible with Dermox?

Possible side effects and safety information

The official safety profile for Dermox (Methoxsalen) is strictly tied to its role as a photosensitizing agent, meaning the adverse reactions are often related to its necessary activation by UVA radiation. The safety profile is organized into categories reflecting different organ systems and levels of seriousness, as documented in regulatory labeling.

Adverse Reactions and Regulatory Classification

Adverse reactions are classified by frequency and by the organ system affected:

  • Skin and Subcutaneous Tissue Disorders dominate the profile, including reactions integral to therapy such as pruritus (itching) and erythema (redness), and potentially severe reactions like blistering and burning following excessive UVA exposure.
  • Common Systemic Effects documented in regulatory sources include Gastrointestinal Disorders (e.g., nausea, vomiting) and Nervous/Psychiatric Disorders (e.g., headache, insomnia, nervousness).

Serious and Long-Term Safety Concerns

The most critical safety documentation pertains to risks associated with cumulative or prolonged use:

  • Carcinogenesis: Long-term exposure to Methoxsalen combined with UVA therapy is officially documented as carcinogenic, significantly increasing the risk of Non-melanoma Skin Cancers, specifically Squamous Cell and Basal Cell Carcinoma.
  • Ocular Damage: There is a documented risk of Cataract formation if the eyes are not adequately protected during and following treatment.

Safety Constraints and Special Populations

Regulatory labeling specifies high-level constraints for use:

  • Contraindications: Use is restricted in individuals with a history of Melanoma, invasive Squamous Cell Carcinoma, specific light-sensitive diseases (e.g., Lupus Erythematosus), or Aphakia (absence of the lens of the eye).
  • Time-Related Patterns: Gastrointestinal effects like nausea are often reported as more common at treatment initiation, while the risks of cancer and cataracts are associated with cumulative, long-term exposure.
  • Pediatric and Hepatic Status: Safety and efficacy have not been established in pediatrics. Caution is required in individuals with hepatic impairment due to the potential for prolonged photosensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of any medication requires immediate medical attention.

An overdose of Dermox may be associated with symptoms that can range from mild discomfort to life-threatening emergencies. The severity of clinical manifestations depends on the amount of medication taken and individual health factors.

Documented Overdose Presentations

Symptoms may affect multiple physiological systems. Common gastrointestinal manifestations include nausea, vomiting, and abdominal pain. Signs affecting the central nervous system may involve drowsiness, confusion, or dizziness. In cases of severe exposure, more serious clinical manifestations can occur, such as seizures, loss of consciousness (coma), or significant changes in vital signs (e.g., breathing pattern or heart rhythm).

Overdose Presentation Key Clinical Manifestations
Gastrointestinal Nausea, vomiting, stomach pain
Neurological Confusion, drowsiness, dizziness
Severe Toxicity Seizures, coma, significant vital sign changes

Required Emergency Action

If you suspect an overdose, call emergency medical services immediately (such as 911 or your local emergency number) or contact a certified poison control center. Do not wait for symptoms to worsen. Be prepared to provide the name of the product, the amount taken, and the time of ingestion. Timely professional treatment is critical for managing symptoms and preventing potential complications like organ damage or cardiorespiratory events.

Therapeutic Uses of Dermox

What Dermox Treats: Main Uses and Benefits

Dermox is commonly used across conditions presenting with acute episodes characterized by significant inflammation and itching, such as conditions involving inflammatory or irritative processes and recurrent or episodic manifestations. This medication is relevant for easing symptoms related to inflammatory and pruritic manifestations in responsive skin conditions. This topical support is applied in clinical settings that involve acute or unstable symptom patterns. Dermox is commonly used to help with easing the overall symptom load. It is often applied during phases of increased distress or discomfort where symptoms become temporarily overwhelming.

Benefits for Symptom Relief

Dermox is primarily applied to symptoms related to inflammatory or irritative states, specifically targeting the redness, swelling, and intense itching that accompany flare-ups. This use may assist with calming the affected area, which contributes to maintaining functional stability when symptoms interfere with routine activities. The medication contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive relief for symptoms related to Intense Itching and Inflammation

Regulatory References

  1. DailyMed (NIH) prescribing information

Eligibility and Restrictions for Use

Who Can and Cannot Use Dermox?

The population eligibility for Dermox (Methoxsalen) is strictly regulated, primarily due to its classification as a potent photosensitizing agent. Regulatory documents define patient groups who are absolutely prohibited from using the medicine and those who require conditional use.

Contraindicated and Restricted Populations

Eligibility Status Official Regulatory Rules
Absolute Contraindication Patients with known hypersensitivity to Methoxsalen or other psoralen compounds.
Individuals with certain light-sensitive diseases (e.g., Lupus Erythematosus, Porphyria Cutanea Tarda, Albinism).
History of melanoma or invasive squamous cell carcinoma.
The absence of the eye lens (aphakia).
Conditional/Restricted Use Pregnancy and Lactation: Use is generally contraindicated or requires extreme caution, as the drug may cause fetal harm and excretion into human milk is not established.
Organ Function: Caution is advised in hepatic impairment due to the risk of prolonged photosensitivity from delayed drug clearance.

Age and Procedural Constraints

The medicine is typically authorized for use in adults. Oral forms have dosing schedules documented for individuals 12 years of age and over, though safety and effectiveness for all formulations are often not established in younger pediatric patients. Specific formulations, such as the sterile solution used in extracorporeal procedures, also carry contraindications related to procedural tolerance, including severe cardiac disease or certain high white blood cell counts, as defined in the regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Dermox (Methoxsalen) identifies interactions based on two major domains: altered drug exposure via metabolic pathways and additive effects that increase sensitivity to light.

Pharmacokinetic Interactions

Methoxsalen is documented as an inhibitor of hepatic enzymes CYP1A2 and CYP3A4. This pharmacokinetic mechanism may increase the plasma concentration and systemic exposure of co-administered medicines that are sensitive substrates of these enzymes, such as Melatonin, Vorasidenib, and Lonafarnib. Co-administration with the drug Fezolinetant is formally classified as a contraindicated combination due to this significant exposure increase via CYP1A2 inhibition.

Pharmacodynamic Interactions and Restrictions

Methoxsalen’s interaction profile includes pharmacodynamic additive effects with other products that cause photosensitivity. Concomitant use with medicinal products like Tetracyclines, Thiazide diuretics, and Phenothiazines is noted to increase the risk of phototoxicity. This risk also extends to naturally photosensitizing substances, such as Psoralen-containing foods like limes, celery, and figs, which are restricted from consumption. A strict timing rule is a mandatory regulatory requirement, specifying that skin and eyes must be protected from all sources of UV light, including sunlight, for a minimum of 8 to 24 hours after oral administration.

Mechanism of Action

The mechanism of Dermox (Methoxsalen) is entirely dependent on its activation by UVA light and operates through two primary biological effects: inhibiting cellular proliferation and stimulating skin pigment production.

️ Light-Activated DNA Modification

Methoxsalen is a photosensitizing agent that remains biologically inert until it absorbs UVA light energy. This photoactivation transforms the drug into a highly reactive molecule that intercalates (inserts itself) into the double helix of DNA. The activated drug then forms covalent cross-links with the pyrimidine bases in the DNA, resulting in the chemical modification of the cell's genetic material. This mechanism provides the initial molecular intervention necessary for its biological effect.

Anti-Proliferative Pathway and Cellular Arrest

The resulting DNA cross-links inhibit the key processes of DNA replication and transcription, which are essential for cell division. This molecular damage leads to the inhibition of cellular proliferation and forces rapidly dividing cells, such as keratinocytes and specific immune cells (T-lymphocytes), into cell cycle arrest. The resulting physiological effect is an anti-proliferative action that results in the reduction of cell turnover.

Melanogenesis and Mechanistic Constraint

The same photo-chemical activation simultaneously influences the melanogenesis pathway by stimulating pigment-producing cells (melanocytes), which results in the increased production and transfer of melanin. The mechanism is fundamentally constrained by its absolute dependency on the energy source; the entire cascade, including both the anti-proliferative and pigment-stimulating effects, cannot proceed unless the drug is appropriately exposed to UVA radiation.

Dosage and Administration Information

How to Use Dermox: Official Administration Guidelines

Methoxsalen (Dermox) is administered through a strictly defined protocol in conjunction with controlled UVA radiation, a therapy known as photochemotherapy. The method of use is determined by the specific condition being addressed, utilizing either a systemic or localized approach.

Administration Scope

Property General Administration Protocol
Route of Administration Oral (for systemic absorption); Topical (for local application); Extracorporeal (for specialized photopheresis in a machine, not direct patient IV).
Dosing Schedule Oral Dosing is typically weight-based, ranging from 0.4 mg/kg to 0.6 mg/kg depending on the specific capsule formulation and indication. Extracorporeal Dosing involves injecting a fixed dose of 200 mcg into the photopheresis system's photoactivation bag.
Frequency and Timing Oral photochemotherapy is administered two or three times per week, maintaining a minimum 48-hour interval between successive treatments. For systemic use, the oral capsule must be taken with food or milk at a mandated time of 1.5 to 4 hours before the scheduled UVA exposure.
Missed Dose Rule If multiple treatments are missed, the associated UVA exposure dose must be reduced; the UVA exposure time should never be increased after a missed dose.
Supervision The administration must occur only under the constant supervision of a physician with special training in photochemotherapy, ensuring the controlled coupling of drug intake and light exposure.

Procedural Structure

The usage protocol requires precise adherence to dosing, mandatory pre-UVA timing, and continuous medical oversight. The ECP method follows an initial cycle of treatment (e.g., 7 cycles), which may be followed by a prolonged maintenance schedule. These official instructions establish a standardized, time-dependent protocol for the medicine’s use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dermox

The information in this section summarizes the clinical research landscape for Methoxsalen (Dermox), based on data cited within the records of official governmental and intergovernmental health authorities. This overview is based strictly on findings from formal studies, such as Randomized Controlled Trials (RCTs) and Long-term Observational Cohorts.

Evidence for Severe, Refractory Psoriasis

Research exploring the use of Methoxsalen in photochemotherapy (PUVA) for severe psoriasis was established through classic, large-scale Multicenter Trials and several Randomized Controlled Trials (RCTs). These studies were evaluated in Adults presenting with moderate-to-severe plaque psoriasis that had not responded to other therapy options. The primary outcomes monitored were objective measures of Clinical Clearing and changes in standardized Disease Severity Scales. Studies tracked patterns related to changes in these scales across the observed populations. The research describing measured changes with topical Methoxsalen in this context is limited.

Evidence for Cutaneous T-Cell Lymphoma (CTCL) and Extracorporeal Photopheresis

The evidence for this clinical situation consists primarily of Phase 2 and Phase 4 Open-Label Trials and Long-term Follow-up Cohort Studies involving adult patients with CTCL. This research also applies to the specialized procedure known as Extracorporeal Photopheresis (ECP), which was studied for this condition. The main clinical outcomes researchers examined were the Overall Clinical Response, measured by documented change in skin lesions, and the Duration of that Observed Change. A key limitation is that many trials used single-arm, open-label designs, and the evidence regarding long-term outcomes is not fully established.

Evidence for Idiopathic Vitiligo

Research exploring Methoxsalen for Restoration of Pigmentation relies on Older Uncontrolled Clinical Studies and smaller Randomized Comparative Trials. Research describes patterns indicating that the Restoration of Pigmentation appears to vary based on lesion location, and evidence was associated with high variability in the measured outcomes among observed patient groups.

Evidence Gaps and Areas of Uncertainty

The research landscape highlights several areas where data remain insufficient or certainty remains low. The evidence indicates that the outcomes for vitiligo can be erratic, making individual outcomes uncertain. Furthermore, data on how measured outcomes apply to very young or very old patients, or those with significant comorbidities, remain insufficient.

How should Dermox be stored and disposed of?

Dermox Storage and Disposal: Official Requirements

Dermox (Methoxsalen) must be stored strictly according to its official labeling to maintain stability and potency as a photosensitizing agent.

Storage Conditions

The medicine, including capsules and solutions, requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from light and kept in a tightly closed container to prevent moisture exposure. It is critical to avoid freezing the medicine. All forms of Dermox must be kept out of the reach of children.

Handling and Disposal

Any unused portion of the sterile solution must be immediately discarded after the procedure. Outdated or unneeded medication should not be kept. Disposal of the product must follow official guidelines, such as utilizing a drug take-back program or the authorized household trash method, and should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagMexico

Equivalent of Dermox found in:

A-Z Index: